Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Jemberlin, here is I believe the link for complaints,
https://tts.sec.gov/oiea/Complaint.html
Hopefully all AMTD holders will get on board. If they get enough complaints about AMTD, they will probably take action. I see some of our Canadian friends are also on the warpath!
AMTD needs to get investigated by the SEC. Their refusal to allow purchases of AMBS and only sales speaks loudly, especially since no other broker is doing this. Contact the SEC, email....got to their sight, easy to do. I sent one out this morning. Enough complaints, and they will look into it. Take the 10 minutes and do it, TODAY!
Warp I'm also with amtd, sorry to say. That is going to change. I really believe they have a large short position. I think we should initiate a class action suit for damages.....Not sure how it works, but I may seriously look into it. AMTD needs to have their feet held to the fire!
Blackhawks, thank you for your usual level headed responce, to set things straight. Should be hearing something from MJFF either way. That statement that further study is warranted sounds pretty positive, but we will see. LYMPRO is the gem in the near term, and positive developments there will move this stock north I believe, soon hopefully!
thanks for your sense of humor! sorely needed here!
I wonder if a class acton suit might be in order for AMTD? Any one know what the mechanisim is, and how it works? the chill on AMBS with AMTD is bogus, nothing less. The threat of a law suit might get their attention??!!
Well said, Muka1! Patience will here be rewarded. Things could change radically with on substantive PR. Gerald, make it happen!
Over 500k liquid, and financing from individuals and institution uderway. AMBS is forging ahead, and has succeeded in a biotech's greatest challenge, FUNDING. Their portfolio of MANF and LYMPRO is binging in the cash. Good things coming soon, very soon I believe.
" We have been successful in raising convertible note financing from various individual investors over the last several months and more recently have raised a significant amount of funds from a specific financial institution. This is an encouraging trend that we expect to continue as we continue operations. We will continue to use commercially-reasonable efforts going forward to raise equity financing and other financing instruments to raise sufficient capital to continue operations and meet our major milestones" 10Q
200,200,200,500 HIKE! Hopefully the MM's will cut it loose this week. Substantial news very near I do believe!
I have had TDAMTD for too long. I have been very suspicious that they are short AMBS and have alterior motives for the "chill" explanation. I do believe that is the case. I checked with Fidelity about moving my acc't but can't transfer AMBS because it is a BB stock, only can liquidate. Will have to transfer cash direct, sell in the AMTD account....will take some time, but going to do it soon....
LYMPRO is the catalyst that is going to move AMBS back towards .10 in a hurry if they can get the process started, and from the updated 8k, specifically the 6.6 is very clear. The Lymphocyte Proliferation (LymPro) test for Alzheimer’s disease is a diagnostic test that has the potential to become standard protcol in medical practices worldwide. Gerald and the AMBS boards understand this perfectly and are ramping up preperations for brings this to mkt likely this year. Revenues will follow immediately. As has been stated earlier, this will not require the lengthy human trials but will be greatly accelerated. The LYMPRO white paper 6.6 update, ""finalizing agreements with its projected GLP" says it all. They are making this the number one priority. Manf with all its potential, and JV possibilites will come later. Get er done Gerald!!
That oops, that was then hastily removed, and replaced by todays ammended 8k, and the reposted LYMPRO white paper 6.6. This is a flashing "all hands on deck" signal from Gerald. Will be very surprised if we don't have some very significant news before the end of the month that could easily break us out again above .10! Holding, and can't wait for full disclosure, and confirmation of a deal! Could arrive any day.
Pivotal statement on that 8K just out, with the ammended LYMPRO white paper. Something is obviously going on here, which will be fully disclosed in short order, probably before the end of the month, likely next week. When the GLP partner is announced with the timeline, the chase will be on. This obviously has people's attention today, and there will be lots of posts over the weekend. Look for this to pivot back above 5 next week, perhaps even this afternoon. Too near a crucial PR to be out! Next week looks to be a very encouraging week, could be explosive. Still holding all my shares, have not sold any, and won't untill well above .10
Looks like someone thought the better of selling that bloc @ 5. Ust too many possibilities for substantial news at any time. If we get any buying here toward the close, could take out double nickels! Have a great weekend everyone!
MM's gleaning 50k under 5 in first half hour! What a joke!!! No sellers, maybe they will start dumping some to try and shake things up.....Manipulation at its worst. Gerald how about a surprise PR today?
Pert and perhaps others seem to be working in collusion trying to shake out some shares below 5, but without a lot of success. We really don't know where the sells are originating, just manipulation---seems so. 5 seems to be pretty solid, and building a solid base for a breakout on news---real news. Untill then, just more manipulation. There has not been ANY bad news. Expecting some substantial positive news this month. Could come at any time. Patience will be rewarded here I truly believe!
I'm MJFF is well aware of NURO-PRO or soon will be. Why Marks didn't mention that I'm not sure. But if NURO-PRO can get to mkt, as has been mentioned a number of times, the mkt is huge. AMBS obviously has good connections with MJFF and lots of others. This is just the beinging. Good things coming!
Very positive Webinar for AMBS from MJFF.
1) Bill Marks presence and connection to AMBS
2) MJFF recent statements that further study of MANF is warranted, is again underscored today. "More needs to be known"
3) repetitive statements about the importance of early detection of PD to enable earlier treatment by whatever mean
4) the crucial role of NURO-PRO in early detection will open the door to revenues and will fuel the IND studies for MANF.
Nothing but positive. Get NURO-PRO underway asap!
MJFF webcast emphasizes the need for early detection as a key to treatment of PD. NURO-PRO is going to be a huge success if they can get it to mkt!
Dr. Marks appearance is a win win for AMBS. Just the fact that he is a recognized authority on PD, AZ and is invited by MJFF for this CC is an immense authentication from MJFF for AMBS. Couple this with the fact that CERE-120's documented failure also mentioned MANF as "worthy of further study" says MANF is under close observation by MJFF and you can bet by "others". This is an exceptioinal opportunity to be buying at these levels.
Nice work icetea1111!!!!
I knew that MANF was being seen in a new light following CERE-120 failure, but this statement on the MJFF website really brings the uniqueness of MANF into focus. The positive result of the MANF studies are clearly understood, and seen as crucial in the ongoing search for a cure of PD. Fantastic news! Sure puts AMBS in a very positive stance for grant money!! :)
Gerald, thanks for that shot over the starboard bow! Tomorrows conference call on MJFF will be a very interesting glimps into the mindset of the MJFF and how they view MANF with the failure of CERE-120. AMBS, like any upstart biotech could sure use some help, and I am very hopeful that MJFF is going to send some grant money our way. Next two months are going to be exciting, and very positive I do believe!!
Just a little aggressive buying is going to break this loose! 6 could be taken out quickly!
great job Retiredtech! Maybe this is the relationship Gerald referred to about someone with great respect in the market place. Expecting lots of good news over the next couple months.
William Marks invitation to appear on the MJFF panel discussion says volumes about AMBS. This is a legitimate developmental stage biotech company with an advisory board with world class scientists and Doctors, being sought out by none other than the MJFF which has previously awarded AMBS grant money with the possitility of more coming very soon.
"Next week, we invite you to learn more about the future of CERE-120, and trophic factors on the whole. Join the conversation on May 1st at noon ET by signing up for our breaking news Webinar "The Future of Trophic Factors," with MJFF Chief Scientific Advisor/neurturin co-discoverer Gene Johnson, PhD, William Marks, MD, of the University of California San Francisco Medical Center, and MJFF CEO Todd Sherer, PhD.
MJFF Contributing Editor Dave Iverson will host, and a Q&A with participants will follow. Please register to participate!" William Marks presence on this interview coupled with CERE-120 failuare is noteworthy. MJFF had this to say this last week "MJFF: Tell us about some of the other trophic factors in development.
GJ: Many patients are familiar with a trophic factor similar to neurturin called GDNF (glial cell-derived neurotrophic factor). It is in Phase 2 clinical testing with a company called MedGenesis Therapeutix, in collaboration with the United Kingdom's Cure Parkinson's Trust and Parkinson's UK (MJFF has also supported MedGenesis in related work).
Like Ceregene, this company is looking to improve the method for delivering the trophic factor in the brain. MedGenesis is looking to do so by improving the hardware they use to implant, and then monitor, the effect of the trophic factor. MedGenesis' approach would work through chronic intermittent delivery of GDNF into the putamen through a pump system. Ceregene, on the other hand, was testing a one-time surgical approach.
Two other trophic factors in pre-clinical development for PD are CDNF (conserved dopamine neurotrophic factor) and MANF (mesencephalic astrocyte-derived neurotrophic factor). Both have been shown to have interesting effects in a laboratory setting. It's possible that down the road, either of these could prove to be as good, or even better, than GDNF or neurturin, but for now we just don't know. The research is yet to be done. The scientific community currently knows more about CDNF than it does MANF. Ongoing pursuit of both is warranted"
Should be a very interesting interview. MANF's mention by name says volumes. AMBS patents on MANF are begining to be recognized for the potential they may hold to unlock significang advanced in the treatment of PD. The upcoming IND application with FDA is going to bring AMBS onto the world stage in a big way. Patience here is I believe going to be richly rewarded.
Blackhawks I think you are exactly right. But with a Biotech like AMBS the decline in PPS does finally reach a point of balance where the downside risk is somewhere at par with the upside potential. It is begining to look like we may be at that fulcrum point this afternoon. We shall see how the close goes. If it manages to close green, we may have touched the near term bottom. i sure hope so! If the potential moves over into the "actual column, the move up will be quick!
I have, and that is probably where I'm going---Thanks!
Thanks Vickii, mine is the same; no volume under ambse, nut id does have the correct bid and ask under ambse...Here long term too. Very encouraged with what's going on inrrespective of AMTD.
I think that the cusip change, and name change "E" has things screwed up temporarily. I'm on amtd and it is completely screwed up. There is, no bid or ask under AMBS but volume shows correct Level II nothing under AMBS, it is under AMBSE..Very confusing. They will eventually get it right, but they are so BAD!
Any suggestions on where to move my account, I have had it with AMTD.....Any suggestions appreciated.
TDAMTD screwed up as usual. Anyone what is the volume? pps?
tia
The statement on the MJFF website that "ongoing pursuit of MANF studies is warranted" is going to be a tough one for shorts to explain away!Sorry about the errors in the earlier post.I must have hit the enter or erased something accidently.
In any case, the MJFF announcement about CERE_120 failure to meet expectations is going to help AMBS. No need to argue with bashers, just read the objective statements on MJFF website. You may be certain that the scientific community has fully digested what was said,or will shortly, and will be having a fresh look at MANF.This is a truly exciting devlopment. I'm further certain that Gerald and the advisory board will leverage what has happened to the max. Gerald, strike while the iron is hot! Can't wait untill Monday.
Cere-120 faillure may be the event that is going to enable AMBS to gain pivotal attention from the investment community. AMBS recent CC was the catalyst that led to the sell off last week, even though there was no negative news whatsoever. Hopes for a JV announcement were disappointed and many former supporters sold out. However, volume did not portray any mass exodus. Most significant AMBS investors remained steadfast, and were taking the opportunity to add to positions. Geralds MJFF press release says it all! MANF is very much still on the drawing board as a viable candidate for active research in the opionion of MJFF. This press release may cause many who have recently sold to reconsider. Monday could be a pivotal day for AMBSS in more than one way. Have a look at that MJFF press release again. AMBS is still very much in the running and on the drawing boards of not just MJFF! Puts Gerald's overtures with Biotech heavyweight and Big Pharma in an entirely different light! I have not sold any of my position, and may even consider adding early this week. MJFF: Tell us about some of the other trophic factors in development.
GJ: Many patients are familiar with a trophic factor similar to neurturin called GDNF (glial cell-derived neurotrophic factor). It is in Phase 2 clinical testing with a company called MedGenesis Therapeutix, in collaboration with the United Kingdom's Cure Parkinson's Trust and Parkinson's UK (MJFF has also supported MedGenesis in related work).
Like Ceregene, this company is looking to improve the method for delivering the trophic factor in the brain. MedGenesis is looking to do so by improving the hardware they use to implant, and then monitor, the effect of the trophic factor. MedGenesis' approach would work through chronic intermittent delivery of GDNF into the putamen through a pump system. Ceregene, on the other hand, was testing a one-time surgical approach.
Two other trophic factors in pre-clinical development for PD are CDNF (conserved dopamine neurotrophic factor) and MANF (mesencephalic astrocyte-derived neurotrophic factor). Both have been shown to have interesting effects in a laboratory setting. It's possible that down the road, either of these could prove to be as good, or even better, than GDNF or neurturin, but for now we just don't know. The research is yet to be done. The scientific community currently knows more about CDNF than it does MANF. Ongoing pursuit of both is warranted.
Some companies are working on non-surgical approaches to trophic factor therapy. Phytopharm recently completed a study to determine if oral delivery of their medication Cogane might incite the brain to produce more trophic factors on its own. Unfortunately, this trial returned negative results.
It's also possible successful trophic factor therapy might require that patients be treated earlier in the disease, when there are likely more neurons remaining in the brain that could respond to the treatment. In the later stages of the disease, some scientists have hypothesized, there may not be enough healthy neurons left in the brain for the trophic factor to take effect. To date, trophic factor clinical studies have only investigated people at the later stages of Parkinson's. It remains to be seen if trials in early stage patients will happen.
MJFF: What does this mean for the overall pursuit of a disease-modifying treatment?
JE: There are several other disease-modifying approaches for Parkinson's drugs nearing clinical testing that are unrelated to trophic factors. We remain hopeful that one of these other types of approaches could lead to the treatments the Parkinson's community needs.
It's also possible that the field will continue to think about trophic factors in other ways. For example, we know that trophic factors are released during exercise, and we also know that exercise is good for people with PD. Better understandings of this link could contribute to how we target these proteins in the future.
Any informed biotech investor understands that as any potential drug application moves towards, and through Human trials, phase1,I,II,III the potential financial return is understood and translated into an increase in the pps. Does MANF have that potential, absolutely. The IND application that has already been announced is targeted for 2014 which is not far away. AMBS and the advisory board, and the governing board understand the process to the letter. Members of the board, including Dr. Rubinfeld have been sucessfully through it more than once, and are helping to guide AMBS through the process. WIll it ultimately be successful? Only time will tell, but the PPS will incrementally increase as each successive milestone is reached. Can't wait for further updates, and the move to MKT LymPro in the coming months. Lots of exciting things in motion!
Well spoken WarpCore 61! Thank you for the clarification. Absolutely correct, and interestingly, purely Biblical!
MANF's recent validation coupled with CERE-120 failure to meet endpoint targets certainly brings more focus to MANF and of course AMBS. The scientific community is pursuing any and all promising appplications for PD, and MANF is recognized as having promising potential. That IND preperation needs to be on high priority, which I'm sure Gerald understands very well, to say nothing of the AMBS board of directors, and Advisory board. The future is looking very exciting indeed. Gerald, strike when the iron's hot!
good job 1 eyed jack! Have a gr88 weekend!!
thanks HB. Pop a couple and have a relaxing weekend!
for anyone interested, CERE-120 is from Ceregene, check out the MJFF website. Interesting development. Great weekend everyone!
CERE-120 results less than hoped for re. PD treatment, news just out. Certainly not going to hurt MANF in attracting more attention. The Supreme Court certainly has a very pro business stance. Thinking they are going to overtunr mass patents re. genes, etc. is highly unlikely. Too many big guns will be in the treches on that one. Verky uncertain at this juncture. AMBS